Asia Pacific Pregnancy and Ovulation Testing Market Research Report – Forecast to 2027

Asia Pacific Pregnancy & Ovulation Testing Market Research Report: By Type (hCG Detection, Ovulation Testing), by Mode of Purchase (OTC Testing, Prescription Testing), End-User (Hospitals & Clinics, Fertility Centers, Others) - Forecast Till 2027

ID: MRFR/HC/4739-CR | July 2018 | Region: Bric | 91 pages

Asia Pacific Pregnancy Ovulation Testing Market Speak to Analyst Request a Free Sample

Asia Pacific Pregnancy & Ovulation Testing Market Overview

The Asia Pacific pregnancy & ovulation testing market is anticipated to touch USD 298.68 billion by 2023, as per an insightful report by Market Research Future (MRFR). It is expected to exhibit a 6.1% CAGR during the assessment period (2018-2023). The increasing acceptance of home testing kits to check the possibility of pregnancy is projected to spur market demand during the forecast period.

Pregnancy tests are kits capable of detecting hormones such as human chorionic gonadotropin (hCG) in urine. Ovulation tests, on the other hand, are capable of detecting an uptick in luteinizing hormone (LH) to decide the optimal time for conceiving children. Availability of ovulation monitors on e-commerce websites, awareness of fertility tests, and awareness of these tests made possible by various promotional marketing activities by major brands are likely to lead to an uptick in market demand over the forecast period.


Digitization of results to provide privacy to consumers has been made possible owing to pervasiveness of smartphones. For instance, the FIRST RESPONSE Pregnancy PRO Digital Test & App Access by Church & Dwight Co., sends accurate results to the consumer’s smartphone. But high costs of ovulation tests can act as a market deterrent.


Report Overview


This report allows the user to gain a deeper understanding of the ongoing events and trends in the Asia Pacific (APAC) market for pregnancy and ovulation testing. By correlating the historical data with key market dynamics, our analysts can make highly accurate projections in the report. MRFR’s report includes a thorough segmental analysis of the APAC market segmented by type, mode of purchase, end-user, and region with astute insights. This report has been prepared to assist industry participants in making informed decisions on growth strategies and operation management. Users will come across drivers, trends, opportunities, and restraints which are likely to influence the growth of the market during the assessment period.


Segment Overview


By type, the Asia Pacific pregnancy & ovulation testing market has been segmented into pregnancy and ovulation testing. The pregnancy testing segment is sub-segmented into blood-based and urine-based testing. This segment is touted to garner above average demand owing to advances in pregnancy testing kits and alarming cases of polycystic ovary syndrome (PCOS). Similarly, the ovulation testing segment is sub-segmented into fertility monitors and ovulation prediction kits.


By mode of purchase, the Asia Pacific pregnancy & ovulation testing market is segmented into prescription and non-prescription testing/over-the-counter (OTC) testing.  The non-prescription testing mode of purchase is projected to experience remarkable growth thanks to preference for home pregnancy tests and privacy concerns among women.


By end-user, the Asia Pacific pregnancy & ovulation testing market is segmented into fertility centers, hospitals and clinics, and others. The hospitals and clinics segment is likely to register a 5.8% CAGR during the forecast period owing to their propensity to handle large patient volumes.


The segments and sub-segments covered in the report are analyzed under six major regions – India, China, Japan, Republic of Korea, Australia, and Rest of Asia Pacific, with respective country-level market sizing. For the scope of research, the standard definition of the product/service “pregnancy and ovulation testing” is included in the report. The report discusses and interprets the current and future opportunities of the industry by delivering an unbiased growth assessment.


Players Covered


Gregory Pharmaceutical Holdings, Inc., Proctor & Gamble, TaiDoc Technology & Corporation, Mankind Pharma Ltd., Geratherm Medical AG, Fairhaven Health, LLC, Quidel Corporation, Piramal Enterprises Ltd., Cadila Healthcare Limited, and Church & Dwight Co., Inc., are noteworthy players in the Asia Pacific pregnancy and ovulation testing market.


The report offers comprehensive profiles on these market players and assesses their current standing in the Asia Pacific pregnancy and ovulation testing market. Company history coupled with annual turnover, segmental share, SWOT analysis, growth strategies, new product launches, mergers and acquisitions (M&A) activities, and latest R&D initiatives are outlined in the report.


Research Methodology


Market Research Future (MRFR) uses a combination of primary and secondary research to compile market reports. Primary data is accumulated from interviewing industry stalwarts and secondary research is collated by studying white papers and annual reports of leading players. Our analysts use top-down and bottom-up approaches to validate the findings of the report. The report comprises news, current trends, and future prospects related to the market, all of which can provide a thorough understanding of the market to clients. Industry leaders can make accurate business decisions based on our insights.


Analysis Period



  • Base Year - 2017

  • Projection Period - From 2018 to 2023

  • Market Denomination - USD Billion

  • Conversion Rate - Considered as per the respective financial years


Intended Audience



  • Government Research Institutes

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Academic Institutes and Universities


For the scope of research, the report offers a comprehensive analysis of the Asia Pacific pregnancy and ovulation testing market.


Type



  • Pregnancy Testing (hCG Detection)

    • Urine-based Testing

    • Blood-based Testing



  • Ovulation Testing

    • Ovulation Prediction Kits

    • Fertility Monitors




Mode of Purchase



  • Prescription Testing

  • Non-prescription or OTC Testing


End-user



  • Fertility Centers

  • Hospitals & Clinics

  • Others


Region



  • Australia

  • Republic of Korea

  • India

  • China

  • Japan

  • Rest of Asia Pacific



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Asia Pacific Pregnancy and Ovulation Testing Market: Competitive Landscape


Church & Dwight Co., Inc., SPD Swiss Precision Diagnostics GmbH, and Mankind Pharma Ltd collectively accounted for around 28.1% market share of Asia Pacific pregnancy and ovulation testing market in 2017. These companies continue to retain their strong presence through product launch, and FDA approval. As there are plenty of large and small market players available, it is very tricky to analyze their market shares.


SPD Swiss Precision Diagnostics GmbH accounted for the largest market share of the Asia Pacific pregnancy and ovulation testing market. Church & Dwight Co., Inc. accounts for approximately 9.4% share in the pregnancy and ovulation testing market. Mankind Pharma Ltd holds the third position in the Asia Pacific pregnancy and ovulation testing market owing to strong brand value.


In 2017, SPD Swiss Precision Diagnostics GmbH accounted for the largest market share of Asia Pacific pregnancy and ovulation testing market, with around 12.2% of the market share. The large share of the company is attributed to the launch of new products at a very competitive price such as Clearblue Pregnancy Test with Weeks indicator, Clearblue Early Detection Pregnancy Test, Clearblue Rapid Detection Pregnancy Test, Clearblue Digital Early Detection Pregnancy Test, Clearblue Fast & Easy Pregnancy Test, Clearblue Advanced Fertility Monitor, Clearblue Advanced Digital Ovulation Test, Clearblue Digital Ovulation Test, and others. In the last few years, the company has adopted the strategy of introducing a new product by focusing on R&D. For instance, in 2017, The Company launched the Clearblue Connected Ovulation Test System, the first and only ovulation test system to track two unique hormones with smartphone connectivity.


Church & Dwight Co., Inc. held the second position in terms of market share, in 2017. The company focuses on developing and distributing innovative products, which differentiate them from other players around the globe. For instance, in Jan 2016, the company launched FIRST RESPONSE Pregnancy PRO Digital Test & App Access. With this launch, the company expanded its pregnancy test product portfolio. Moreover, the company has a strategy of rising the global market presence through mergers and acquisitions. The company offers products under various brands such as OXICLEAN, ARM & HAMMER, TROJAN, SPINBRUSH, NAIR, ORAJEL, XTRA, FIRST RESPONSE, L’IL CRITTERS, BATISTE, WATERPIK, and VITAFUSION. Church & Dwight Co., Inc. sells home pregnancy and ovulation kits under the FIRST RESPONSE brand such as first response rapid result pregnancy test, first response early result pregnancy test, first response gold digital pregnancy test, first response triple check pregnancy test kit, first response pregnancy pro, and first response daily digital ovulation test


Mankind Pharma Ltd acquired the third spot in the market. The company currently has a presence in 22 countries across Asia, Africa, South-East Asia, and Gulf countries and focused on increasing its worldwide market presence. For instance, Mankind Pharma has set its manufacturing units in the U.S. (September 2017)


There are many other players present in the market such as, Fairhaven Health, LLC, Piramal Enterprises Ltd, Quidel Corporation, TaiDoc Technology & Corporation, Cadila Healthcare Limited, Gregory Pharmaceutical Holdings, Inc. and others that accounts around 71.9% of the Asia Pacific market share. The companies adopted the strategy of FDA approvals and acquisitions to solidify their position in the market.